ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT01399593
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6061
- Registration Number
- NCT01374360
- Locations
- 🇺🇸
Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations., Boston, Massachusetts, United States
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
Phase 2
Completed
- Conditions
- Lysosomal Acid Lipase DeficiencyWolman Disease
- Interventions
- Drug: Sebelipase alfa (SBC-102)
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01371825
A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype
Completed
- Conditions
- Lysosomal Acid Lipase DeficiencyWolman Disease
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01358370
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Cedars-Siani Medical Center, Los Angeles, California, United States
🇺🇸Columbia University, New York, New York, United States
Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1
Terminated
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: ALXN1103
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01335165
- Locations
- 🇵🇱
University Clinical Centre, Dębinki 7, Gdańsk, Poland
🇨🇿Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze, U nemocnice 1, Prague 2, Czech Republic
🇮🇹Federico II University of Naples, Via Pansini 5, Naples, Italy
Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency
Phase 1
Completed
- Conditions
- LAL-DeficiencyLysosomal Acid Lipase DeficiencyCholesterol Ester Storage Disease(CESD)
- Interventions
- Drug: Sebelipase alfa 0.35 mg/kgDrug: Sebelipase alfa 3 mg/kgDrug: Sebelipase alfa 1 mg/kg
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01307098
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
Phase 2
Completed
- Conditions
- Hypophosphatasia
- Interventions
- Biological: asfotase alfa
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01205152
- Locations
- 🇺🇸
Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸St. Vincent Hospital, Green Bay, Wisconsin, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)
Phase 2
Completed
- Conditions
- Hypophosphatasia (HPP)
- Interventions
- Biological: Asfotase Alfa
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01203826
- Locations
- 🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States
🇨🇦Children's Hospital Health Sciences Centre, Winnipeg, Manitoba, Canada
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01194804
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01194973
© Copyright 2025. All Rights Reserved by MedPath